For three years the obesity story has been dominated by one mechanism: GLP-1. Semaglutide hit it. Tirzepatide doubled it up with GIP. Retatrutide piled glucagon on top. Each step pushed Phase 3 weight loss numbers higher — 15%, then 22.5%, then 28.7%.
Eli Lilly just published Phase 2 data on a peptide that does none of that.
Eloralintide is a selective amylin receptor agonist. No GLP-1. No GIP. No glucagon. At 48 weeks, the 9 mg arm produced 20% mean body weight reduction versus 0.4% on placebo, with a side-effect profile that looks tamer than the GLP-1 class. Lilly has already moved it into Phase 3.
That is the news. Here is what it means.
What Is Eloralintide?
Eloralintide (development code LY3841136) is a long-acting, selective amylin receptor agonist designed for once-weekly subcutaneous injection. It is structurally engineered for stability and selectivity at amylin receptors — and it deliberately avoids cross-activation of the GLP-1, GIP, and glucagon receptors that drive every other major obesity peptide on the market or in late-stage development.
Amylin is a 37-amino-acid hormone co-secreted with insulin from pancreatic beta cells after meals. Its physiologic role is straightforward: slow gastric emptying, blunt the post-meal glucagon surge, and signal satiety to the hindbrain. Native amylin aggregates and is hard to formulate, which is why pramlintide (a synthetic analog) requires multiple daily injections and saw limited adoption. Eloralintide is the long-acting answer that pramlintide never delivered.
The Phase 2 Trial
The trial enrolled 263 adults with obesity or overweight plus at least one weight-related comorbidity across 46 U.S. research centers (Lancet, December 2025). Participants were randomized to placebo or one of six eloralintide regimens for 48 weeks of treatment.
Mean Weight Loss at 48 Weeks
| Arm |
Mean Weight Loss |
| Eloralintide 9 mg |
20% |
| Eloralintide 6–9 mg escalation |
20% |
| Eloralintide 6 mg |
18% |
| Eloralintide 3–9 mg escalation |
16% |
| Eloralintide 3 mg |
12% |
| Eloralintide 1 mg |
9% |
| Placebo |
0.4% |
Every active dose hit statistical superiority over placebo on the primary endpoint. Secondary cardiometabolic readouts — waist circumference, blood pressure, lipids, glycemic markers, inflammation — all moved in the right direction.
Safety Profile
The headline tolerability finding: nausea was dose-dependent and ranged from 11% at the 1 mg dose to 64% at the 9 mg dose, versus 14% on placebo. Fatigue tracked similarly (0–46% vs 12% placebo). Most events were mild to moderate. Slower dose-escalation arms had lower GI burden than the matched fixed-dose arms — meaning titration appears to mitigate tolerability problems, which is exactly the playbook that worked for the GLP-1 class.
This matters because amylin's mechanism (gastric emptying, central satiety) overlaps GLP-1 enough that GI side effects were expected. They showed up. They titrated out. Nothing in the safety dataset jumped out as novel or class-specific.
Compare Top Peptides
Best vendor pricing, COA verified, with active discount codes
Why an Amylin-Only Result Matters
To understand why the eloralintide data is more interesting than "another weight loss drug," compare it against what we already knew about amylin:
| Drug |
Class |
Weight Loss |
Notes |
| Semaglutide 2.4 mg |
GLP-1 |
~15% (STEP 1, 68 wk) |
Approved obesity therapy |
| Tirzepatide 15 mg |
GLP-1 + GIP |
~22.5% (SURMOUNT-1, 72 wk) |
Approved obesity therapy |
| Retatrutide 12 mg |
GLP-1 + GIP + glucagon |
28.7% (TRIUMPH-4, 68 wk) |
Phase 3, NDA pending |
| Eloralintide 9 mg |
Amylin only |
20% (Phase 2, 48 wk) |
Phase 3 starting |
| Cagrilintide 2.4 mg (mono) |
Amylin only |
~10% (Phase 2, 26 wk) |
Combined with sema as CagriSema |
| CagriSema |
Amylin + GLP-1 |
22.7% (REDEFINE 1, 68 wk) |
NDA filed |
Two takeaways:
- Amylin alone produces tirzepatide-level weight loss in mid-stage trials. That is not what the prior cagrilintide monotherapy data suggested. Eloralintide's pharmacology — long half-life, selective receptor agonism — apparently extracts substantially more from the amylin pathway than older amylin analogs did.
- The mechanism isn't GLP-1. That opens combinations and patient populations that GLP-1 saturation closes off. Patients who don't tolerate GLP-1 nausea profiles, patients who stall out on GLP-1 monotherapy, and patients whose providers want to layer mechanisms instead of escalating GLP-1 doses all become a market.
For an analytical look at why pure GIP/glucagon and non-GLP-1 mechanisms are starting to matter, see our breakdown of why GLP-1 may not be needed for the next wave of weight loss drugs.
Where Eloralintide Sits in Lilly's Pipeline
Lilly is running parallel obesity programs at unusual breadth:
- Tirzepatide — approved, dominant in market.
- Retatrutide — Phase 3, TRIUMPH program ongoing, NDA filing planned for late 2026.
- Orforglipron — oral small-molecule GLP-1, Phase 3 (approval pathway).
- Eloralintide — selective amylin, Phase 3 starting late 2026.
- Quintuple agonist — preclinical, GLP-1 + GIP + glucagon + amylin + calcitonin in a single molecule. ADA 2026 abstract scheduled (Poster 2839-LB, June 7).
The strategic logic is clear: Lilly is building a portfolio where amylin is one of several reusable building blocks. Eloralintide validates amylin as a standalone mechanism. The quintuple agonist would fold that mechanism back into a combined molecule. Both directions hedge against any single mechanism (GLP-1 included) failing to deliver durability.
What This Means for Peptide Buyers Today
Eloralintide itself is not available outside Lilly's clinical program. But the read-through to the broader peptide research market is real:
For the broader vendor landscape and current discount codes across the obesity-peptide category, see our /deals page.
What to Watch Next
- Phase 3 enrollment timeline. Lilly announced "by year-end 2026." A delay or acceleration here changes the 2028–2029 approval math.
- Eloralintide + tirzepatide or eloralintide + orforglipron combinations. This is where Lilly's portfolio strategy becomes obvious. A combined amylin + GLP-1 product would compete directly with CagriSema, but with Lilly's distribution muscle behind it.
- The quintuple agonist preclinical readout at ADA 2026 (June 7). If the rat data holds, eloralintide-class amylin pharmacology will be folded into a single molecule alongside everything else.
- Real-world durability. Phase 2 ran 48 weeks. The hard question for amylin monotherapy is whether the 20% weight loss holds at 2 to 3 years, where every existing obesity drug shows attenuation.
References
| Citation |
Topic |
| Bays HE et al., Lancet (Dec 2025) PMID 41207310 |
Eloralintide Phase 2 48-week obesity trial |
| Lilly press release, ObesityWeek 2025 |
Eloralintide Phase 2 topline + Phase 3 announcement |
| Lilly investor announcement, Feb 2026 |
TRIUMPH-4 retatrutide topline (28.7% weight loss) |
| NEJM 2025; CagriSema REDEFINE 1 (PMID 40544432-related) |
CagriSema Phase 3 weight loss benchmark |
| Wilding JPH et al., N Engl J Med 2021; 384:989 |
Semaglutide STEP 1 trial |
| Jastreboff AM et al., N Engl J Med 2022; 387:327 |
Tirzepatide SURMOUNT-1 trial |
This article is reporting on investigational research compounds. Eloralintide is not approved by the FDA. Nothing here constitutes medical advice. Consult a licensed clinician for treatment decisions.